Jiangsu Hengrui Pharmaceuticals (01276): The injection of Rilconquidian Monoclonal Antibody is included in the list of breakthrough treatment varieties.

Jiangsu Hengrui Pharmaceuticals (01276) announced that its subsidiary, Suzhou Shendeya Biopharmaceutical Co., Ltd., has had its injection of Rucaparib antibody (SHR-A1811) included in the list of breakthrough therapeutic drugs by the National Medical Products Administration Drug Evaluation Center. This marks the 10th indication for which Rucaparib antibody has received breakthrough therapy certification. The injection of Rucaparib antibody was approved for market in China in May 2025 and is indicated for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have previously received at least one systemic therapy. According to data from the EvaluatePharma database, the total global sales of similar products in 2024 amounted to approximately $6.57 billion. As of now, the cumulative research and development investment in the injection of Rucaparib antibody project is around 17.725 billion yuan (unaudited).